Nautilus Biotechnology reports Q4 EPS (14c), consensus (18c)

Cash, cash equivalents, and investments were $206.3M as of December 31, 2024. “2024 was a year of innovation and meaningful accomplishment for Nautilus,” said Sujal Patel, CEO. “From unveiling the world’s first quantitative measurement of biological variation in tau proteoforms potentially associated with Alzheimer’s Disease, to fundamental platform development advancements, I’m pleased with the progress of last year. Our revised timeline expectations for commercial launch are based on efforts required to implement modifications to our platform’s assay configuration and surface chemistry that we believe will significantly reduce technical risk and yield the greatest possible platform performance.”